Nuclear receptors: Difference between revisions

No edit summary
No edit summary
Line 96: Line 96:
Similar differences may be observed between ER which has bound the partial agonist and complete antagonist ligands. <scene name='71/714947/Antagonist_tamoxifen_bound_er/5'>Antagonist tamoxifen bound ER</scene> The most drastic difference is noticeable between agonist and antagonist ligands. Compare the agonist scene to the <scene name='71/714947/Agonist_estradiol_bound_er/2'>Agonist estradiol bound er</scene>. Special attention should be given to the bottom right alpha helices and beta sheets that are pushed out more in the antagonist compared to the agonist bound ER.  
Similar differences may be observed between ER which has bound the partial agonist and complete antagonist ligands. <scene name='71/714947/Antagonist_tamoxifen_bound_er/5'>Antagonist tamoxifen bound ER</scene> The most drastic difference is noticeable between agonist and antagonist ligands. Compare the agonist scene to the <scene name='71/714947/Agonist_estradiol_bound_er/2'>Agonist estradiol bound er</scene>. Special attention should be given to the bottom right alpha helices and beta sheets that are pushed out more in the antagonist compared to the agonist bound ER.  


Tamoxifen (an ER antagonist) is a drug created to bind ER and inhibit the transcription factor activity of ER. Tamoxifen is larger than the normal hormone ER binds (estradiol); for this reason added with the conformation estrogen receptor takes on, the activation loop is pushed into an inactive conformation. The picture below shows structural differences between the (left/blue) antagonist tamoxifen bound ER and the (right/tan) agonist estradiol bound ER. This blocks ER from giving the signal to grow. Antagonists are generally larger and cause estrogen receptors to be too hindered sterically to be able to bind to the major groove of DNA, inhibiting the receptor. The antagonist bound estrogen receptor is noticeably larger than the agonist bound version. Further inhibition occurs when ER has bound an antagonist ligand. Antagonist bound ER is still brought to Euchromatin in the nucleus. The larger than agonist bound ER ligand chaperon complex is not capable of binding the major groove of DNA, but still occupies the space around specific palindromic sites which ER binds and modifies the transcription of local genes to these palindromic sequence areas. This blocks agonist bound ER from being able to reach these specific palindromic major groove target loci in DNA.
===Estrogen receptor α===
===Estrogen receptor α===
* [[Estrogen receptor#Estrogen receptor α complexed with raloxifene and a corepressor peptide]]
* [[Estrogen receptor#Estrogen receptor α complexed with raloxifene and a corepressor peptide]]
* [[Tamoxifen|Tamoxifen and the Estrogen receptor]]
 
===Estrogen receptor β===
===Estrogen receptor β===
* [[Student Project 10 for UMass Chemistry 423 Spring 2015]]
* [[Student Project 10 for UMass Chemistry 423 Spring 2015]]

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Michal Harel